Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Neogenomics Inc
(NQ:
NEO
)
16.52
+0.10 (+0.61%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Neogenomics Inc
< Previous
1
2
3
4
5
6
Next >
NeoGenomics to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
August 29, 2024
From
NeoGenomics, Inc.
Via
Business Wire
NeoGenomics Reports Second Quarter 2024 Results
July 29, 2024
From
NeoGenomics, Inc.
Via
Business Wire
NeoGenomics to Report Second Quarter 2024 Financial Results on July 29, 2024
July 09, 2024
From
NeoGenomics, Inc.
Via
Business Wire
Fort Myers’ Mayor to Proclaim June as NeoGenomics’ Commitment to Cancer Month
June 13, 2024
From
NeoGenomics, Inc.
Via
Business Wire
NeoGenomics Reports Third Quarter 2023 Results
November 06, 2023
Via
ACCESSWIRE
NeoGenomics Reports Second Quarter 2023 Results
August 08, 2023
Via
ACCESSWIRE
NeoGenomics to Introduce Comprehensive Lung Solution & Feature Hematopathology Services at ASCO, Offering Actionable Insights to Support Treatment Management
May 28, 2024
From
NeoGenomics, Inc.
Via
Business Wire
NeoGenomics Reports First Quarter 2024 Results
April 30, 2024
From
NeoGenomics, Inc.
Via
Business Wire
NeoGenomics Announces Senior Leadership Promotions
April 18, 2024
From
NeoGenomics, Inc.
Via
Business Wire
NeoGenomics to Report First Quarter 2024 Financial Results on April 30, 2024
April 09, 2024
From
NeoGenomics, Inc.
Via
Business Wire
NeoGenomics Showcases Commitment to Transforming Cancer Patient Care at AACR 2024 Annual Meeting
March 27, 2024
From
NeoGenomics, Inc.
Via
Business Wire
NeoGenomics Releases Inaugural Environmental, Social, and Governance (ESG) Report
March 20, 2024
From
NeoGenomics, Inc.
Via
Business Wire
NeoGenomics to Participate in the TD Cowen 44th Annual Health Care Conference
March 01, 2024
From
NeoGenomics, Inc.
Via
Business Wire
NeoGenomics Reports Fourth Quarter and Full Year 2023 Results
February 20, 2024
From
NeoGenomics, Inc.
Via
Business Wire
NeoGenomics Signs Working with Cancer Pledge in Support of Employees
February 01, 2024
From
NeoGenomics, Inc.
Via
Business Wire
NeoGenomics to Report Fourth Quarter and Full Year 2023 Financial Results on February 20, 2024
January 30, 2024
From
NeoGenomics, Inc.
Via
Business Wire
Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030
January 30, 2024
EQNX::TICKER_START (OTCQB:TDSGF),(TSXV:TELO),(NYSE:BMY),(NYSE:TMO),(NASDAQ:NTRA),(NASDAQ:NEO) EQNX::TICKER_END
Via
FinancialNewsMedia
ROSEN, A LEADING NATIONAL FIRM, Encourages NeoGenomics, Inc. Investors to Inquire About Securities Class Action Investigation – NEO
January 02, 2024
From
The Rosen Law Firm, P.A.
Via
Business Wire
NeoGenomics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
January 02, 2024
From
NeoGenomics, Inc.
Via
Business Wire
Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030
January 30, 2024
From
FN Media Group LLC
Via
GlobeNewswire
NeoGenomics to Appeal Ruling
December 28, 2023
Via
ACCESSWIRE
NeoGenomics to Present New Data at San Antonio Breast Cancer Symposium Highlighting Utility of RaDaR for Therapy Response
December 05, 2023
Via
ACCESSWIRE
NeoGenomics to Participate at the Piper Sandler 35th Annual Healthcare Conference
November 14, 2023
Via
ACCESSWIRE
NeoGenomics Announces the Commercial Availability of Two New Tests, Expanding Its Next-Generation Sequencing and Lung Cancer Portfolios
October 24, 2023
Via
ACCESSWIRE
NeoGenomics to Report Third Quarter 2023 Financial Results on November 6, 2023
October 17, 2023
Via
ACCESSWIRE
Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030
October 17, 2023
EQNX::TICKER_START (OTCQB:TDSGF),(TSXV:TELO),(NASDAQ:GH),(NASDAQ:NTRA),(NYSE:DGX),(NASDAQ:NEO) EQNX::TICKER_END
Via
FinancialNewsMedia
NeoGenomics Announces Medicare Coverage for RaDaR Assay for Minimal Residual Disease and Recurrence in Breast Cancer
July 27, 2023
Via
ACCESSWIRE
NeoGenomics to Report Second Quarter 2023 Financial Results on August 8, 2023
July 18, 2023
Via
ACCESSWIRE
NeoGenomics Expands Board of Directors with Appointments of Three Independent Directors
June 29, 2023
Via
ACCESSWIRE
NeoGenomics' RaDaR Assay for Minimal Residual Disease Receives First Commercial Coverage
June 15, 2023
Via
ACCESSWIRE
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.